KRAS and neoplasm: Despite the study’s limitations, such as the retrospective approach and the limited and selected number of enrolled patients, our data confirm that the monitoring of the appearance of tumour molecular alterations (i.e., KRAS) in ctDNA at baseline and during treatment is a promising and reliable tool to detect treatment resistance, anticipating the clinical evidence of disease progression and, thus, allowing us a rational change in cancer therapy.